- At least 18 years of age
- Estrogen and/or progesterone receptor positive adenocarcinoma of the breast with
evidence of 1) unresectable 2)locally recurrent, or 3) metastatic disease
- Postmenopausal
- ECOG [Eastern Cooperative Oncology Group] =1
- Evaluable(e.g bone only disease allowed) and Measurable disease [RECIST (Response
Evaluation Criterion in Solid Tumors)]
- HER2 [Human Epidermal Growth factor Receptor 2] positive disease not previously
treated with herceptin
- Any prior anti-angiogenic therapy, endocrine or cytotoxic anti-cancer therapy in the
metastatic disease setting
- Radiation therapy within 2 weeks of first study treatment